BACKGROUND: Daily inhaled corticosteroid (ICS) use is the cornerstone of asthma management, although it is often suboptimal, especially in inner-city populations. OBJECTIVE: To assess the impact of potentially modifiable medication beliefs on adherence with ICS therapy across time. METHODS: Asthma history, medication beliefs, and ICS therapy adherence were determined in a prospective, observational cohort. Medication beliefs were based on self-regulation and self-efficacy theory. Self-reported adherence with ICS therapy was assessed using the Medication Adherence Reporting Scale, a validated 10-item instrument, at baseline and at 1 and 3 months. Repeated-measures multivariable regression identified beliefs independently associated with adherence across time after adjusting for age, sex, race, and asthma severity. RESULTS: The 261 patients were low-income minorities with high rates of asthma hospitalization, emergency department visits, intubation, and oral corticosteroid use. Adherence with ICS therapy was stable across time, with 70% of patients saying that they used ICS all or most of the time when asymptomatic. Most patients (82%) thought it was important to use ICS when asymptomatic, although 49% worried about side effects and 37% worried about becoming addicted. Although 82% felt confident in using ICS, 7% felt that their regimen was hard to follow. In multivariable analyses, the odds of adherence increased for those who felt that using ICS when asymptomatic was important (odds ratio [OR], 4.15) and for those who were confident in using ICS (OR, 2.23) and decreased by worries about side effects (OR, 0.52) or feeling the regimen was hard to follow (OR, 0.48). CONCLUSIONS: Several positive and negative beliefs about ICS were associated with adherence. Eliciting and addressing these potentially modifiable beliefs may help improve adherence and outcomes.
BACKGROUND: Daily inhaled corticosteroid (ICS) use is the cornerstone of asthma management, although it is often suboptimal, especially in inner-city populations. OBJECTIVE: To assess the impact of potentially modifiable medication beliefs on adherence with ICS therapy across time. METHODS: Asthma history, medication beliefs, and ICS therapy adherence were determined in a prospective, observational cohort. Medication beliefs were based on self-regulation and self-efficacy theory. Self-reported adherence with ICS therapy was assessed using the Medication Adherence Reporting Scale, a validated 10-item instrument, at baseline and at 1 and 3 months. Repeated-measures multivariable regression identified beliefs independently associated with adherence across time after adjusting for age, sex, race, and asthma severity. RESULTS: The 261 patients were low-income minorities with high rates of asthma hospitalization, emergency department visits, intubation, and oral corticosteroid use. Adherence with ICS therapy was stable across time, with 70% of patients saying that they used ICS all or most of the time when asymptomatic. Most patients (82%) thought it was important to use ICS when asymptomatic, although 49% worried about side effects and 37% worried about becoming addicted. Although 82% felt confident in using ICS, 7% felt that their regimen was hard to follow. In multivariable analyses, the odds of adherence increased for those who felt that using ICS when asymptomatic was important (odds ratio [OR], 4.15) and for those who were confident in using ICS (OR, 2.23) and decreased by worries about side effects (OR, 0.52) or feeling the regimen was hard to follow (OR, 0.48). CONCLUSIONS: Several positive and negative beliefs about ICS were associated with adherence. Eliciting and addressing these potentially modifiable beliefs may help improve adherence and outcomes.
Authors: Emmanuelle M Clerisme-Beaty; Susan J Bartlett; W Gerald Teague; John Lima; Charles G Irvin; Rubin Cohen; Mario Castro; Robert A Wise; Cynthia S Rand Journal: J Allergy Clin Immunol Date: 2011-02 Impact factor: 10.793
Authors: Juan Carlos Cardet; Margee Louisias; Tonya S King; Mario Castro; Christopher D Codispoti; Ryan Dunn; Linda Engle; B Louise Giles; Fernando Holguin; John J Lima; Dayna Long; Njira Lugogo; Sharmilee Nyenhuis; Victor E Ortega; Sima Ramratnam; Michael E Wechsler; Elliot Israel; Wanda Phipatanakul Journal: J Allergy Clin Immunol Date: 2017-05-20 Impact factor: 10.793
Authors: Taylor L Brooks; Howard Leventhal; Michael S Wolf; Rachel O'Conor; Jose Morillo; Melissa Martynenko; Juan P Wisnivesky; Alex D Federman Journal: J Gen Intern Med Date: 2014-08-05 Impact factor: 5.128
Authors: Alex D Federman; Michael Wolf; Anastasia Sofianou; Elizabeth A H Wilson; Melissa Martynenko; Ethan A Halm; Howard Leventhal; Juan P Wisnivesky Journal: Patient Educ Couns Date: 2013-03-21
Authors: Katherine Krauskopf; Alex D Federman; Minal S Kale; Keith M Sigel; Melissa Martynenko; Rachel O'Conor; Michael S Wolf; Howard Leventhal; Juan P Wisnivesky Journal: COPD Date: 2014-06-24 Impact factor: 2.409